Other mutations, namely c.19_47del, c.668dupA, c.915T>A, c.2418dupA, c.2433delC, c.5030_5033delCTAA in BRCA1 and c.249delG, c.632-1G>A in BRCA2 do not overlap with previously reported breast or ovarian cancer cluster regions. This evidence concerns the gene BRCA2 and ovarian carcinoma.